<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004285</url>
  </required_header>
  <id_info>
    <org_study_id>199/11704</org_study_id>
    <secondary_id>U01DK046109</secondary_id>
    <secondary_id>U01DK046114</secondary_id>
    <secondary_id>U01DK046126</secondary_id>
    <secondary_id>U01DK046140</secondary_id>
    <secondary_id>U01DK046143</secondary_id>
    <secondary_id>U01DK049240</secondary_id>
    <secondary_id>U01DK049241</secondary_id>
    <secondary_id>U01DK049242</secondary_id>
    <secondary_id>U01DK049243</secondary_id>
    <secondary_id>U01DK049244</secondary_id>
    <secondary_id>U01DK049249</secondary_id>
    <secondary_id>U01DK049252</secondary_id>
    <secondary_id>U01DK049254</secondary_id>
    <secondary_id>U01DK049259</secondary_id>
    <secondary_id>U01DK049261</secondary_id>
    <secondary_id>U01DK049264</secondary_id>
    <secondary_id>U01DK049271</secondary_id>
    <nct_id>NCT00004285</nct_id>
  </id_info>
  <brief_title>Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis</brief_title>
  <acronym>HEMO</acronym>
  <official_title>Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Los Angeles Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Main Line Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate whether hemodialysis providing a 2-pool, variable volume urea kinetic
      modelling value of 1.05 versus 1.45 reduces mortality and morbidity in patients with end
      stage renal disease.

      II. Compare the efficacy of high versus low flux dialyzer membranes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified by center,
      age, and diabetes prior to dialysis initiation.

      Patients are randomly assigned to 1 of 4 groups: moderate dose dialysis, low flux membrane;
      high dose dialysis, low flux membrane; moderate dose dialysis, high flux membrane; or high
      dose dialysis, high flux membrane. Moderate dose is a target eKt/V of 1.05 and high dose is
      1.45. The dose and delivery of dialysis are measured monthly by the equilibrated fractional
      clearance of urea (eKt/V) calculated with double pool kinetics.

      Patients are dialyzed 3 times a week in the shortest possible time (minimum 2.5 hours),
      adjusted for adequate fluid removal. General medical care, protein and calorie intake, and
      dialyzer reuse and other aspects of dialysis therapy are standardized. The protocol document
      lists approved dialyzers; no unsubstituted cellulosic membranes are permitted.

      The intervention phase of this study is 5 years. Patients are followed for survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1995</start_date>
  <completion_date type="Actual">December 31, 2001</completion_date>
  <primary_completion_date type="Actual">December 31, 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First hospitalization for cardiac causes or death from any cause</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First hospitalization for infection or death from any cause</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First &gt;15% decrease in albumin or death from any cause</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All hospitalizations not related to vascular access</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardiac causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First hospitalization or death due to cardiac causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to infection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First hospitalization or death due to infection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1846</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Standard dose, low flux hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose, high flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, low flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, high flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard dose, low flux hemodialysis</intervention_name>
    <arm_group_label>Standard dose, low flux hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard dose, high flux hemodialysis</intervention_name>
    <arm_group_label>Standard dose, high flux hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High dose, low flux hemodialysis</intervention_name>
    <arm_group_label>High dose, low flux hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High dose, high flux hemodialysis</intervention_name>
    <arm_group_label>High dose, high flux hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  End stage renal disease that requires in-center hemodialysis 3 times/week On
             hemodialysis for at least 3 months (6 months following renal transplant)

          -  No scheduled renal transplant from living donor

        --Prior/Concurrent Therapy--

          -  No concurrent intervention studies unless ancillary to this protocol No concurrent
             investigational drugs

        --Patient Characteristics--

          -  Hepatic: Albumin at least 2.6 g/dL by nephelometry No cirrhosis with encephalopathy or
             abnormal PT

          -  Renal: Urea clearance (interdialytic) no greater than 1.5 mL/min per 35 liters total
             urea volume

          -  Cardiovascular: No New York Heart Association class IV congestive heart failure
             despite maximal therapy No unstable angina No new onset angina No recent exacerbation
             of frequency, duration, or severity of angina

          -  Pulmonary: No chronic pulmonary disease requiring supplemental oxygen

          -  Other: Not hospitalized in acute or long term care facility at entry No active
             malignancy requiring chemotherapy or radiotherapy No AIDS No active systemic
             infection, e.g., tuberculosis or fungal infection No mental incompetence or other
             contraindication to protocol therapy Not pregnant Geographically available for
             treatment at participating institution No more than 20 missed treatments/year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B. Ornt</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G. Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials. 2000 Oct;21(5):502-25.</citation>
    <PMID>11018567</PMID>
  </reference>
  <results_reference>
    <citation>Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9.</citation>
    <PMID>12490682</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>end stage renal disease</keyword>
  <keyword>rare disease</keyword>
  <keyword>renal and genitourinary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data and samples are available at the NIDDK central repository</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

